We recently compiled a list of the 12 Best Healthcare Stocks to Buy According to Analysts. In this article, we are going to take a look at where Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stands ...

Equities researchers at Zacks Research lifted their Q4 2024 earnings estimates for Sarepta Therapeutics in a research note issued to investors on Monday, February 3rd. Zacks Research analyst S.

Nisa Investment Advisors LLC grew its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 23.1% ...

Top-line Phase 3 trial data show ambulatory boys with Duchenne continued with motor improvements two years after a single ...

Elevidys, Sarepta's gene therapy for DMD, has emerged as the company's primary growth engine. Following its label expansion to include patients aged 6 years and older, the therapy has seen increased ...

In year two of the trial, Elevidys demonstrated statistically significant and clinically improvements across three key ...

Elevidys, Sarepta's gene therapy for DMD, has emerged as the company's primary growth engine. Following its label expansion to include patients aged 6 years and older, the therapy has seen ...